drugset / Trial / NCT02321540
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Phase 1/2
Completed
13 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collabPharmacyclics LLC. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of Part 1 of this clinical research study is to find the highest dose of (Imbruvica) ibrutinib that can be given to patients with non-small cell lung cancer (NSCLC). The goal of Part 2 of this clinical research study is to learn if the dose of ibrutinib found in Part 1 can help to control the disease. The safety of this drug will also be studied in both parts of the study.
Timeline
- Start
- 2015-03-31
- Primary completion
- 2021-09-16
- Completion
- 2021-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |
| Subject | Ibrutinib | Small molecule | 840 mg | Oral |